Algeta shows off impressive Alpharadin Phase III data
This article was originally published in Scrip
Algeta has presented results from the Phase III ALSYMPCA study with Alpharadin (radium-223 chloride), which met its primary endpoint and was terminated ahead of schedule earlier this year so that patients in the placebo arm could be offered the treatment (scripintelligence.com, 7 June 2011). These data raise the bar for Exelixis, which has a rival drug candidate, cabozantinib, trailing in clinical development.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.